No detectable increase in pregnancy risks after GLP-1 exposure around conception, largest review to date finds
Exposure to GLP-1 weight-loss and diabetes drugs around conception is not linked to a clearly detectable increase in adverse outcomes for mothers or babies, according to the largest study of its kind, involving more than 2.1 million pregnancies and led by researchers at City St George's.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Master protocol trials could reimagine the future of rare disease research
United Kingdom
-
Warm temperatures curb appetite but can still promote weight gain, animal experiments find
United Kingdom
-
New model predicts growth hormone therapy response in children with short stature
United Kingdom
-
HIV services plunge at four providers in Uganda and Zimbabwe after U.S. aid cuts
United Kingdom
-
Health services may be missing the link between alcohol problems and eating disorders, study suggests
United Kingdom
-
New workflow rapidly identifies deadly fungal bloodstream infections
United Kingdom
-
Virtual patients could help flag medical device risks missed by conventional studies
United Kingdom
-
Outside school hours care program helps kids be more active and stay off screens
United Kingdom